We therefore conducted an investigator-initiated, single-arm single-center phase II trial of nilotinib to evaluate the safety and antitumor activity in patients with PDGFR inhibitor-naive progressive or recurrent high-grade gliomas enriched for PDGFR-alpha pathway. The gene discussed is PDGFRA; the disease is central nervous system cancer.